PBM Impact On Off-Patent Industry Condemned At Senate Hearing
Discussion Before US Senate Finance Committee Has Been Praised By The Biosimilars Forum
Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.
